Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection-Reference-Cited by-同舟云学术

Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection

Published:2016-08-10 Issue:3 Volume:47 Page:E142-E151
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Nishiguchi Shuhei¹,Urano Yasuhisa²,Suzaki Keiko²,Taniguchi Atsushi²,Scherer Joseph³,Berger Kristi L.³,Quinson Anne-Marie³,Stern Jerry O.³,Omata Masao⁴

Affiliation:

1. Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Japan

2. Nippon Boehringer Ingelheim Co., Ltd.; Tokyo Japan

3. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield Connecticut USA

4. Department of Gastroenterology; Yamanashi Prefectural Central Hospital; Kofu Japan

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12741/fullpdf

Reference23 articles.

1. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1;Hepatol Res,2014

2. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial;Hayashi;J Hepatol,2014

3. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study;Kumada;Hepatol Res,2014

4. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies;Izumi;J Gastroenterol,2014

5. Potency, safety, and pharmacokinetics of the NS3/4A A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection;Manns;J Hepatol,2011